Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 2

Status

Recruiting 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 2

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 7Lymphoma, B-Cell 6Lymphoma, Non-Hodgkin 5Hematologic Diseases 5Lymphoma 2Leukemia, B-Cell 2Recurrence 1Lymphoma, Mantle-Cell 1Leukemia, Lymphoid 1Chromosome 17 deletion 1

Interventions

ofatumumab 3venetoclax 2pirtobrutinib 2obinutuzumab 2ibrutinib 2Chlorambucil 2acalabrutinib 1Tablets 1Observation 1Cholecalciferol 1Bendamustine Hydrochloride 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Leukemia, B-Cell × pirtobrutinib × Clear all
NCT07342478 2026-05-14

ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL

Newave Pharmaceutical Inc

Phase 3 Recruiting
306 enrolled
LymphoidOther hematologic neoplasm

Chromosome 17 deletion, Recurrence, Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell

NCT05254743 2026-04-20

BRUIN-CLL-314

Eli Lilly and Company

Phase 3 Recruiting
662 enrolled
LymphoidOther hematologic neoplasm

Hematologic Diseases, Leukemia, Lymphoid, Lymphoma, Non-Hodgkin, Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡